TD Asset Management
RPTX

TD Asset Management’s Repare Therapeutics RPTX Stock Holding History

TD Asset Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,758
Closed -$275K – 1436
2023
Q3 		$275K Hold
22,758
– – ﹤0.01% 1350
2023
Q2 		$241K Hold
22,758
– – ﹤0.01% 1359
2023
Q1 		$224K Hold
22,758
– – ﹤0.01% 1369
2022
Q4 		$335K Sell
22,758
-6,505
-22% -$97.3K ﹤0.01% 1341
2022
Q3 		$352K Sell
29,263
-5,445
-16% -$70.1K ﹤0.01% 1350
2022
Q2 		$486K Sell
34,708
-13,822
-28% -$163K ﹤0.01% 1297
2022
Q1 		$691K Sell
48,530
-19,298
-28% -$286K ﹤0.01% 1298
2021
Q4 		$1.43M Buy
67,828
+22,928
+51% +$540K ﹤0.01% 1210
2021
Q3 		$1.18M Hold
44,900
– – ﹤0.01% 1213
2021
Q2 		$1.5M Buy
+44,900
New +$1.47M ﹤0.01% 1165

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TD Asset Management's RPTX Position: Q4 2023 in Review

TD Asset Management sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 22,758 shares — an estimated $275K sold.

TD Asset Management first reported a position in RPTX in Q2 2021 and held it in 10 quarters. The position peaked at $1.5M in Q2 2021. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • TD Asset Management reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • TD Asset Management sold 22,758 Repare Therapeutics shares in Q4 2023, an estimated $275K.
  • TD Asset Management first reported a position in Repare Therapeutics in Q2 2021 and held it in 10 quarters.
  • TD Asset Management's Repare Therapeutics position peaked at $1.5M in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on TD Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.